由眼未来主办的 第二届全球眼科大会（Global Ophthalmology Conference 2026） 将于 2026年3月19日 在北京 中关村展示中心 举办。 本届大会延续 "医工融合 × 科技创新 × 临床价值" 的整体定位，聚焦眼科成像、屈光与近视、创新治疗、手术技术、临床前验证等多领域趋势，呈现眼科产 业科技的前沿全景。 大会同期开放 「2026全球眼科年度奖项」申报及《全球眼科创新白皮书》联合撰写席位 ，诚邀各方团队共筑权威成果、共享国际平台。 首届眼科大会回顾 报名方式见以下链接： 奖项申报通知！第二届全球眼科大会 白皮书合作 | 《2026全球眼科创新白皮书》共建计划 大会亮点概览 首届眼科大会回顾 会场与展区 年度白皮书发布： 大会现场发布 《2026全球眼科创新白皮书》 。 奖项盛典： 颁发 "眼科创新系列大奖" ，树立行业标杆，让创新被看见。 精品展位与深度互动： 会场核心区设有 精品展位 ，为赞助商提供与全场高质量决策者面对面洽谈、产品演示与合作签约的高效平台。 创新Demo Hour： 十余家精选创新团队进行 5–10分钟 高密度路演 ，直击投资与合作需求，打造前沿技术首发阵 ...

Core Viewpoint - The article highlights the recent policy support from the Shanghai government aimed at promoting high-quality development in the pharmaceutical and medical device industries, focusing on innovation and regulatory reforms [1][4][6]. Group 1: Policy Support and Regulatory Reforms - The Shanghai government has issued measures to support clinical research for innovative traditional Chinese medicine (TCM) and the development of classic TCM formulas [1][5]. - Clinical trial review and approval timelines for eligible innovative drugs will be shortened to 30 working days, with efforts to promote pilot experiences [4][7]. - The establishment of a service list for key research products in areas such as cell and gene therapy, rare diseases, and artificial intelligence medical devices is emphasized [4][5]. Group 2: Focus on Innovation in Medical Devices and Pharmaceuticals - The article discusses the encouragement of medical institutions to accelerate the development and use of self-researched in vitro diagnostic reagents [7]. - It mentions the establishment of a standardized mechanism for collecting real-world evidence from human experience data to support drug registration applications [5][6]. - The article outlines the importance of enhancing clinical data standardization and the establishment of an evaluation mechanism for innovative medical devices based on clinical value [4][5]. Group 3: Market Outlook and Investment Opportunities - Several brokerage firms express optimism about the innovation in the medical device and pharmaceutical sectors, particularly in the context of recent market adjustments [2][8]. - The article notes that the pharmaceutical sector's fundamentals remain strong, with a focus on innovative drugs and the potential for recovery in underperforming segments [9][10]. - It highlights the expected growth in the small nucleic acid drug sector, driven by technological breakthroughs and increased commercialization [9][10].